Laboratory Services

PD-L1

Optimize Your Cancer Therapy Trials with PD-L1 Testing

Why Choose CelLBxHealth's PD-L1 Service?

The Test…

CelLBxHealth’s PD-L1 service is an end-to-end solution using cutting edge CTC technology with the potential to facilitate:

  • Minimally invasive liquid biopsy
  • Identification and enumeration of CTCs
  • Highly accurate, repeatable, and precise PD-L1 CTC results
  • Early competitive advantage by understanding therapeutic response sooner
  • Optimized patient selection
  • Reduced trial size, costs and time
  • Longitudinal monitoring of PD-L1 status on phenotypic variety of CTCs

The Service…

CelLBxHealth’s extensive experience in CTC testing, combined with our global presence, ensures:

  • Exceptional data quality and timely reporting
  • Global clinical study support
  • Flexibility to accommodate your clinical study schedule

PD-L1 assessment can help investigate the mechanisms of cancer progression and evolution

Contact us

Representative Staining of a CTC Cluster from a Lung Cancer Patient

Representative staining of a CTC cluster from a lung cancer patient

Mesenchymal CTCs isolated using the Parsortix Platform from a lung cancer patient and stained with the Portrait Flex assay with additional PD-L1 marker. CTCs show PD-L1 expression (purple = mesenchymal markers, green= epithelial markers, orange = PD-L 1, blue = nucleus, and red = blood lineage markers (white in merged image)).

Ask How Else We Can Help You

CelLBxHealth’s clinical laboratory offers a suite of complementary CTC enrichment and analysis solutions to enhance your cancer therapy clinical studies.

 

For example, why not consider adding DNA Damage Response (DDR) assessment in CTCs to your PD-L1 service?

CelLBxHealth's PD-L1 service may help stratify or identify suitable patients for your clinical trial.
DDR (measured via yH2AX and pKAP1 expression) may be used to monitor the drug or therapy’s efficacy by showing double strand breaks on heterogeneous CTCs.
Together, these markers could potentially help guide expansion of the patient population eligible for targeted therapy (PDL1 +/-) and then longitudinally monitor both PD- L1 and DDR status to evaluate therapy efficacy.

PD-L1 – the full-service solution to help unlock precision medicine for your patients

Interested in knowing how PD-L1 can help with your clinical trial testing? Leave your name and email address and we will be in touch with more information.

    Resources Related to PD-L1

    Portrait®PD-L1 - Optimize your cancer therapy trials

    Publications

    October, 2023

    Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotyping

    Institute of Cancer and Genomic Sciences, University of Birmingham, UK, published by the British Journal of Cancer

    Open PDF

    Publications

    August, 2023

    Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
    Open PDF

    Publications

    March, 2023

    Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients
    Open PDF

    Publications

    May, 2022

    Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer
    Open PDF

    Publications

    December, 2021

    Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients
    Open PDF

    For Research Use Only. Not For Use in Diagnostic Procedures.

    Request a meeting with